The Soluble Urokinase-Type Plasminogen Activator Receptor as a Biomarker for Survival and Early Treatment Effect in Metastatic Colorectal Cancer

SIMPLE SUMMARY: Patients with metastatic colorectal cancer are likely to have a poor outcome. Chemotherapy is the primary treatment, but because of toxicity and a lack of benefit for a large group of patients, it is important to monitor the treatment effect. The only tool for evaluating treatment ef...

Descripción completa

Detalles Bibliográficos
Autores principales: Blomberg, Kristian, Hansen, Torben F., Brasen, Claus L., Madsen, Jeppe B., Jensen, Lars H., Thomsen, Caroline B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8534079/
https://www.ncbi.nlm.nih.gov/pubmed/34680247
http://dx.doi.org/10.3390/cancers13205100

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8534079/
https://www.ncbi.nlm.nih.gov/pubmed/34680247
http://dx.doi.org/10.3390/cancers13205100

Ejemplares similares